
Does Medicare Cover Mycotoxin Testing?
Mycotoxins are toxic compounds that certain types of molds and fungi produce. They occur naturally but can contaminate food and some indoor environments.
Common mycotoxins include:
Aflatoxins: Different types of aflatoxins grow in soil, rotting vegetation, hay, grains, cereals, corn, sorghum, wheat, rice, soybeans, peanuts, sunflower seeds, cotton seeds, chili and black pepper, coriander, turmeric, ginger, pistachio nuts, almonds, walnuts, coconuts, and Brazil nuts.
Ochratoxins: These types can contaminate foods, including cereals and cereal products, coffee beans, dry vine fruits, wine, grape juice, spices, and licorice.
Patulin: These can be found in rotting fruit, with the main dietary sources found in apples and apple juice made from affected fruit.
Fusarium fungi: These are often found in cereal crops, wheat, oats, and maize.
Tests for mycotoxins and Medicare coverage
A doctor or healthcare professional may order tests to look for signs of myotoxicity, such as a blood serum test, skin prick testing for particular mold allergens, a bronchial challenge test, or urinalysis.
Medicare Part B will typically cover these tests as long as they are medically essential. There are no out-of-pocket costs for these clinical diagnostic lab tests.
Symptoms of mycotoxicity
Mycotoxins can cause mild to more serious health conditions and some of the symptoms you may experience can include:
coughing
wheezing
nasal congestion
skin rashes
watery eyes
itching
muscle aches
fatigue
liver damage
Additionally, people with weakened immune systems may experience heightened sensitivity to mycotoxins.
Reducing the risk of mycotoxins
You can minimize health risks related to mycotoxins by:
Inspecting your food items: Inspect whole grains like corn, wheat, rice, dried figs, and nuts, including peanuts, Brazil nuts, pistachios, walnuts, almonds, coconuts, and hazelnuts. Throw out foods that look moldy, have discoloration, or are shriveled.
Ensuring freshness of food: Buy grains and nuts that are as fresh as possible.
Taking care of food storage: Ensure your foods are stored correctly by keeping them dry, not too warm, and free from insects. Try not to keep foods for long periods before you use them and adhere to packing 'use by' dates.
Diversifying your diet: Eating a variety of foods can help reduce your exposure to mycotoxins.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.


Fox News
10 minutes ago
- Fox News
Trump admin official analyzes the public's response to Trump's economic success
Counselor to the Treasury Secretary Joe Lavorgna discusses approval ratings for President Donald Trump's economy on 'The Ingraham Angle.'